Study of Iron Sucrose With Erythropoietin and Vitamin C to Improve Anemia in Adults Undergoing Major Heart Surgery

What this Trial Is About

Researchers are evaluating an innovative combination therapy to improve perioperative anemia in patients undergoing major cardiac surgery. This approach combines iron sucrose, human erythropoietin, and vitamin C to promote red blood cell production and enhance iron metabolism. Unlike previous treatments that used only intravenous iron, this strategy aims to address multiple factors affecting anemia by supporting both iron utilization and erythropoiesis more comprehensively. Participants in the combination therapy group receive three treatments during the week before surgery 200 mg of iron sucrose by intravenous infusion, 150 IUkg of recombinant human erythropoietin by subcutaneous injection, and 2 mg of vitamin C by intravenous infusion. The comparison group receives conventional anemia treatments routinely used by the surgical team, which may include clinical observation, oral or intravenous iron, blood transfusions, or other measures. All treatments are documented carefully by the study team. During the study, researchers monitor hemoglobin levels on postoperative day 5 as the primary outcome. They also assess the amount of blood products used, changes in hemoglobin, ferritin, and reticulocyte levels, and the incidence of complications such as acute kidney injury, infections, allergic reactions, and serious adverse events up to six months after surgery. Hospital stay duration, readmission rates, and healthcare costs are also evaluated. Participants are followed until hospital discharge or up to one year after surgery, with ongoing safety and health assessments throughout this period.

Effect of the Combined Programme on Perioperative Anaemia（CPPA）